Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for ...
Merck, known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an ...
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America ...
Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary ...
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart ...
Offering counselling plus nicotine replacement therapy (a treatment that provides nicotine in a safer form than tobacco smoking to help people reduce cravings and withdrawal symptoms), during a stay ...
If your night-time routine currently consists of mindlessly scrolling through TikTok in the dark, tossing and turning, trying ...
Abivax SA ABVX on Monday shared additional Phase 3 maintenance data for investigational ulcerative colitis therapy obefazimod ...
(Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results